Date:	12/20/2022	
Your Name:_	Adam Hines	
Manuscript T	Title: EGFR L861Q Mutation in Synchr	onous De-Novo Small Cell and Non-Small Cell Lung Cancer: Molecular
Interrogation	on Identifies Origin and Potential Option	ons for Targeted Therapy
Manuscript r	number (if known): PCM-22-67	
		close all relationships/activities/interests listed below that are ed" means any relation with for-profit or not-for-profit third

related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	_XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	X_None	
	pending		
9	Participation on a Data	_XNone	
	Safety Monitoring Board or		
10	Advisory Board	X None	
10	Leadership or fiduciary role in other board, society,	_XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_XNone	
12	Receipt of equipment,	_XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	X None	
	financial interests		
Ple	ase summarize the above co	nflict of interest in the foll	lowing box:
ı	None		

Date:	12/20/2022	
Your Nam	ne:Sunita Patruni	
Manuscrij	pt Title: EGFR L861Q Mutation	in Synchronous De-Novo Small Cell and Non-Small Cell Lung Cancer: Molecular
Interrogat	tion Identifies Origin and Poter	ntial Options for Targeted Therapy
Manuscri	pt number (if known): PCM-22-	67
related to	the content of your manuscrip	ou to disclose all relationships/activities/interests listed below that are pt. "Related" means any relation with for-profit or not-for-profit third by the content of the manuscript. Disclosure represents a commitment

to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u>

manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial X_None	planning of the work
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pastXNone	36 months
3	Royalties or licenses	_XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
6	educational events Payment for expert	X None	
U	testimony	XNone	
	,		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	X_None	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	_XNone	
12	Descript of a surjust set	V Nava	
12	Receipt of equipment, materials, drugs, medical	_XNone	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	_XNone	
	illianciai iliterests		
Plea	ase summarize the above co	nflict of interest in the foll	owing box:
Γ.			
	lone		

Date:	12/20/2022	
Your Name:	Nidhi Kataria _	
Manuscript 7	Title: EGFR L861Q Mutat	ion in Synchronous De-Novo Small Cell and Non-Small Cell Lung Cancer: Molecular
Interrogation	n Identifies Origin and P	otential Options for Targeted Therapy
Manuscript i	number (if known): PCM	-22-67
•		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial X_None	planning of the work
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pastXNone	36 months
3	Royalties or licenses	_XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
6	educational events Payment for expert	X None	
U	testimony	XNone	
	,		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	X_None	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	_XNone	
12	Descript of a surjust set	V Nava	
12	Receipt of equipment, materials, drugs, medical	_XNone	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	_XNone	
	illianciai iliterests		
Plea	ase summarize the above co	nflict of interest in the foll	owing box:
Γ.			
	lone		

Date:	12/20/2022
	Jeff Boyd
Interrogation	Title: EGFR L861Q Mutation in Synchronous De-Novo Small Cell and Non-Small Cell Lung Cancer: Molecula n Identifies Origin and Potential Options for Targeted Therapy number (if known): PCM-22-67
related to the parties whose to transpare	est of transparency, we ask you to disclose all relationships/activities/interests listed below that are not content of your manuscript. "Related" means any relation with for-profit or not-for-profit third se interests may be affected by the content of the manuscript. Disclosure represents a commitment ency and does not necessarily indicate a bias. If you are in doubt about whether to list a /activity/interest, it is preferable that you do so.
The followin	ng questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	_XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
6	educational events Payment for expert	X None	
U	testimony	XNone	
	,		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	X_None	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	_XNone	
12	Descript of a surjust set	V Nava	
12	Receipt of equipment, materials, drugs, medical	_XNone	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	_XNone	
	illianciai iliterests		
Plea	ase summarize the above co	nflict of interest in the foll	owing box:
Γ.			
	lone		

Date	e:12/20/2022		
You	r Name:Nagashree	e Seetharamu	
Man	nuscript Title: EGFR L861Q N	Nutation in Synchronous D	e-Novo Small Cell and Non-Small Cell Lung Cancer: Molecula
	rrogation Identifies Origin a		•
Man	nuscript number (if known):	PCM-22-67	
relate part to trelate The man	ted to the content of your name ies whose interests may be cansparency and does not not interest, it following questions apply the content only.	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. is preferable that you do the author's relationship vities/interests should be <u>c</u>	os/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains
med In ite	lication, even if that medica	tion is not mentioned in the	all relationships with manufacturers of antihypertensive he manuscript. I in this manuscript without time limit. For all other items,
		T	
		Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	l planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
2	in item #1 above).	V None	
3	Royalties or licenses	_XNone	
4	Consulting fees	X None	
4	Consulting ICCS		

5	Payment or honoraria for lectures, presentations,	XNone				
	speakers bureaus,					
	manuscript writing or					
	educational events	V. Nava				
6	Payment for expert testimony	XNone				
	testimony					
7	Support for attending meetings and/or travel	XNone				
8	Patents planned, issued or	X_None				
	pending					
9	Participation on a Data	X None				
	Safety Monitoring Board or	_XNone				
	Advisory Board					
10	Leadership or fiduciary role	_XNone				
	in other board, society, committee or advocacy					
	group, paid or unpaid					
11	Stock or stock options	_XNone				
12	Receipt of equipment,	X None				
12	materials, drugs, medical	_XNone				
	writing, gifts or other services					
13	Other financial or non-	_XNone				
	financial interests					
Plea	Please summarize the above conflict of interest in the following box:					
1	lone					

Date:_____12/20/2022_

Consulting fees

_X__None

You	r Name: Daniel Ale	exander King		
Mar	nuscript Title: EGFR L861Q M	lutation in Synchronous D	e-Novo Small Cell and Non-Small Cell Lung Cancer: Molec	ular
Inte	rrogation Identifies Origin a	nd Potential Options for 1	argeted Therapy	
Mar	nuscript number (if known):	PCM-22-67		
		-	relationships/activities/interests listed below that are	
rela	ted to the content of your n	nanuscript. "Related" mea	ins any relation with for-profit or not-for-profit third	
part	ties whose interests may be	affected by the content o	f the manuscript. Disclosure represents a commitment	
			If you are in doubt about whether to list a	
rela	tionship/activity/interest, it	is preferable that you do	so.	
	.			
	•	o the author's relationship	os/activities/interests as they relate to the <u>current</u>	
mar	nuscript only.			
The	author's relationships/activ	vities/interests should be o	defined broadly. For example, if your manuscript pertains	
	•		all relationships with manufacturers of antihypertensive	
	lication, even if that medica	• •	• • • • • • • • • • • • • • • • • • • •	
In it	em #1 below, report all sup	port for the work reported	d in this manuscript without time limit. For all other items	i.
	time frame for disclosure is	•		,
		рассос		
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as needed)		
		Time frame: Since the initia	al planning of the work	
1	All support for the present	X None	parming or the nork	
1	manuscript (e.g., funding,			
	provision of study materials,			
	medical writing, article			
	processing charges, etc.)			
	No time limit for this item.			
_		Time frame: pas	t 36 months	
2	Grants or contracts from	XNone	<u> </u>	
	any entity (if not indicated			
2	in item #1 above). Royalties or licenses	X None		
3	noyalties of licelises	_XNone		

5	Payment or honoraria for lectures, presentations,	XNone				
	speakers bureaus,					
	manuscript writing or					
	educational events	V. Nava				
6	Payment for expert testimony	XNone				
	testimony					
7	Support for attending meetings and/or travel	XNone				
8	Patents planned, issued or	X_None				
	pending					
9	Participation on a Data	X None				
	Safety Monitoring Board or	_XNone				
	Advisory Board					
10	Leadership or fiduciary role	_XNone				
	in other board, society, committee or advocacy					
	group, paid or unpaid					
11	Stock or stock options	_XNone				
12	Receipt of equipment,	X None				
12	materials, drugs, medical	_XNone				
	writing, gifts or other services					
13	Other financial or non-	_XNone				
	financial interests					
Plea	Please summarize the above conflict of interest in the following box:					
1	lone					